Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin

Michele Malaguarnera, Massimo Motta, Marco Vacante, Giulia Malaguarnera, Filippo Caraci, Giuseppe Nunnari, Caterina Gagliano, Carmela Greco, Giuseppe Chisari, Filippo Drago, Gaetano Bertino

Research output: Contribution to journalArticle

Abstract

Chronic hepatitis C is both a virologic and a fibrotic disease, with mortality resulting mainly from the complications of cirrhosis and HCC. The aim was to evaluate the impact on of supplementation with a new pharmaceutical complex of silybinvitamin E-phospholipids in patients with chronic hepatitis C treated with Pegylated-Interferon-α2b plus Ribavirin. In this prospective, randomized, placebo controlled, double blind clinical trial, 32 subjects with chronic hepatitis, received Pegylated-Interferon-α2b (1.5 mg/kg per week) plus Ribavirin and placebo, while 32 subjects received the same dosage of Pegylated-Interferon-α2b plus Ribavirin plus association of Silybin 47 mg + vitamin E 15 mg + phospholipids 97 mg in two pill for 12 months. Serum levels of the following markers of liver fibrosis were evaluated: transforming growth factor beta, hyaluronic acid, metalloproteinase 2, amino-terminal pro-peptide of type III procollagen, tissue inhibitor of matrix metalloproteinase type I. The comparison between group A and group B showed a significant difference in ALT (P

Original languageEnglish
Pages (from-to)2510-2518
Number of pages9
JournalAmerican Journal of Translational Research
Volume7
Issue number11
Publication statusPublished - 2015

    Fingerprint

Keywords

  • Hepatitis C
  • Interferons
  • Liver fibrosis
  • Ribavirin
  • Silybin

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Malaguarnera, M., Motta, M., Vacante, M., Malaguarnera, G., Caraci, F., Nunnari, G., Gagliano, C., Greco, C., Chisari, G., Drago, F., & Bertino, G. (2015). Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. American Journal of Translational Research, 7(11), 2510-2518.